Position in EXEL
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$2,502
+$530 QoQ
Shares Held
46
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#697
of 739 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Dunhill Financial, LLC holds $54,530 across 31 Biotechnology names. EXEL ranks #6 (4.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EDIT |
Editas Medicine, Inc.
|
4,000 | $12,960 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
24 | $11,921 | |
| 3 | FATE |
Fate Therapeutics Inc
|
3,180 | $8,586 | |
| 4 | INSM |
INSMED Inc
|
38 | $4,051 | |
| 5 | BEAM |
Beam Therapeutics Inc.
|
75 | $2,574 | |
| 6 | EXEL |
Exelixis, Inc.
This page
|
46 | $2,502 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4 | $2,494 | |
| 8 | INCY |
Incyte Corp
|
21 | $2,380 |
All Filings in EXEL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,502 | 46 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $1,972 | 46 | Shares | Sole | 2026-05-06 | |
| 2025-12-31 | $262 | 6 | Shares | Sole | 2026-01-29 | |
| No filing history on record for this holder in this stock. | ||||||